- Home
- FIVN vs NVCR Comparison
FIVN vs NVCR Comparison
Compare FIVN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- NVCR
- Stock Information
- Founded
- FIVN 2001
- NVCR 2000
- Country
- FIVN United States
- NVCR Switzerland
- Employees
- FIVN N/A
- NVCR N/A
- Industry
- FIVN EDP Services
- NVCR Medical/Dental Instruments
- Sector
- FIVN Technology
- NVCR Health Care
- Exchange
- FIVN Nasdaq
- NVCR Nasdaq
- Market Cap
- FIVN 2.8B
- NVCR 2.3B
- IPO Year
- FIVN 2014
- NVCR 2015
- Fundamental
- Price
- FIVN $42.09
- NVCR $22.09
- Analyst Decision
- FIVN Strong Buy
- NVCR Buy
- Analyst Count
- FIVN 17
- NVCR 5
- Target Price
- FIVN $57.65
- NVCR $33.40
- AVG Volume (30 Days)
- FIVN 1.6M
- NVCR 700.2K
- Earning Date
- FIVN 02-20-2025
- NVCR 02-27-2025
- Dividend Yield
- FIVN N/A
- NVCR N/A
- EPS Growth
- FIVN N/A
- NVCR N/A
- EPS
- FIVN N/A
- NVCR N/A
- Revenue
- FIVN $1,041,938,000.00
- NVCR $577,738,000.00
- Revenue This Year
- FIVN $15.54
- NVCR $19.97
- Revenue Next Year
- FIVN $10.46
- NVCR $2.83
- P/E Ratio
- FIVN N/A
- NVCR N/A
- Revenue Growth
- FIVN 14.44
- NVCR 14.63
- 52 Week Low
- FIVN $26.60
- NVCR $11.70
- 52 Week High
- FIVN $64.70
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- FIVN 56.09
- NVCR 36.77
- Support Level
- FIVN $40.02
- NVCR $21.38
- Resistance Level
- FIVN $43.62
- NVCR $22.95
- Average True Range (ATR)
- FIVN 2.08
- NVCR 0.86
- MACD
- FIVN 0.06
- NVCR 0.01
- Stochastic Oscillator
- FIVN 26.67
- NVCR 34.25
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.